Table 2 Pathological and tumor regression (N = 32)

From: Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

Characteristic

Patients, No. (%)

Pathological T stage (ypT)

 ypT0

9 (28.1%)

 ypT1

3 (9.4%)

 ypT2

6 (18.8%)

 ypT3

11 (34.4%)

 ypT4

3 (9.4%)

 Combined ypT0–2

18 (56.3%)

 Combined ypT3–4

14 (43.8%)

Pathological N stage

 ypN0

23 (71.9%)

 ypN1

6 (18.8%)

 ypN2

2 (6.2%)

 ypN3

1 (3.1%)

 Combined ypN1–3

9 (28.1%)

TRG

 TRG 0

9 (28.1%)

 TRG 1

5 (15.6%)

 TRG 2

14 (43.8%)

 TRG 3

4 (12.5%)

 Combined TRG 0–1

14 (43.8%)

Tumor residual percentage

 0%

9 (28.1%)

 1–10%

7 (21.9%)

 11–50%

12 (37.5)

 51–100%

4 (12.5%)

 MPR (0–10%)

16 (50.0%)

  1. Data are n (%). Percentages may not add up to 100 because of rounding. TRG, tumor regression grade; MPR, major pathological response
Back to article page